Abstract: Novel sulfamoyl-substituted phenethylamine derivatives which exhibit .alpha.-adrenergic blocking action and are useful as an antihypertensive agent and an agent for the treatment of congestive heart failure.

Abstract: Novel heterocyclic compounds shown by the general formula ##STR1## or the pharmaceutically acceptable salts thereof useful as medicament in particular as antagonist of slow reacting substance of anaphylaxis (SRS-A).

Abstract: Various 7-amino-3-substituted-methyl-3-cephem-4-carboxylic acids and lower alkylsily derivatives such as 7-amino-3-(2,3-cyclopenteno-1-pyridiniomethyl)-3-cephem-4 -carboxylic acid iodide and trimethylsilyl 7-trimethylsilylamino-3 -(5,6,7,8-tetrahydro-2-isoquinoliniomethyl)-3-cephem-4 -carboxylate iodide are valuable intermediates in the preparation of new and novel antibacterial agents. A new process for the preparation of these acids and the derivatives has been devised.

Abstract: Novel microorganisms belonging to the genus Micromonospora capable of producing antibiotics YS-02930 K-D, -E or -H represented by formula: ##STR1## wherein R represents a hydrogen atom or a formyl group and a dotted line represents a double bond or a bond shown by: ##STR2## are disclosed. The antibiotics are produced by culturing bacteria belonging to the genus Micromonospora capable of producing at least one antibiotic selected from YS-02930 K-D, -E and -H and, harvesting antibiotic YS-02930 K-D, -E or -H.

Abstract: A novel plaster structural assembly is provided for iontophoresis wherein th e assembly is comprised of an electrode layer and a medicament-containing layer in which a water supplying layer is disposed between the electrode layer and the medicament-containing layer with a sealing cover disposed on the outside of the electrode layer. A method for using the structural assembly for iontophoresis is also provided.

Abstract: The present invention provides pyridine derivatives of following general formula (I) or a physiologically acceptable acid addition salt thereof: ##STR1## wherein R.sub.1 is a hydrogen atom or a hydroxy group, R.sub.2 and R.sub.3, which may be the same or different, each is a lower alkyl group, and n is an integer of 1 to 6. The invention also provides for producing the pyridine derivative and pharmaceutical compositions containing the same. The compounds (I) possess anti-arrhythmic activity.

Abstract: Novel isoflavone derivatives are provided which have the formula ##STR1## and which exhibit cancerocidal and immunosuppressive activity. The invention also provides pharmaceutical compositions containing the derivatives, methods of use and processes for their preparation.

Abstract: This invention relates to novel heterocyclic compounds structurally characterized by containing a specific heterocyclic group and by the presence of --CH.sub.2 --S-- directly bound to the specific heterocyclic group. These heterocyclic compounds are useful as medicines, particularly as antagonists of SRS-A (slow reacting substance of anaphylaxis).

Abstract: The present invention relates to novel phenoxy derivatives represented by the formula (I): ##STR1## wherein: A is an imidazolyl group, a pyridyl group, a pyridyloxy group, an oxo-substituted chromenyloxy group, a lower alkyl group, an amino group which may be substituted with a phenyl group or a lower alkyl group, or a carbamoyl group substituted with a cyclohexylamino group or an imidazolylalkyl group;B is a single bond, a thiazolyl group which may be substituted with a lower alkyl group, a group represented by the formula: --(CH.sub.2).sub.n --O--, --(CH.sub.2).sub.n CONH(CH.sub.2).sub.k -- or --(CH.sub.2).sub.n --N(R.sup.4)-- wherein k is 0 or an integer of 1 to 5, n is an integer of 1 to 6 and R.sup.4 is hydrogen or a lower alkyl group;m is 0 or an integer of 1 to 6;R.sup.1 is a hydroxyl group, an amino group or a lower alkoxy group;R.sup.2 and R.sup.3 which may be the same or different, represent a hydrogen atom or a lower alkyl group hereafter the same:and salts thereof.

Abstract: The present invention relates to novel phenoxy derivatives represented by the formula (I): ##STR1## wherein: A is an imidazolyl group, a pyridyl group, a pyridyloxy group,B is group represented by the formula: --(CH.sub.2).sub.n --O--, --(CH.sub.2).sub.n CONH(CH.sub.2).sub.k -- or --(CH.sub.2).sub.n-N (R.sup.4)-- wherein k is 0 or an integer of 1 to 5, n is an integer of 1 to 6 and R.sup.4 is hydrogen or a lower alkyl group;m is 0 or an integer of 1 to 6;R.sup.1 is a hydroxyl group, an amino group or a lower alkoxy group;R.sup.2 and R.sup.3 which may be the same or different represent, a hydrogen atom or a lower alkyl group hereafter the same, having lipid lowering activity, and salts thereof.

Abstract: Mycaminosyl tylonolide derivatives represented by the following general formula ##STR1## (wherein R.sup.1 denotes hydroxyl group, a lower alkanoyloxy group, benzoyloxy group, azido group, or amino group which mat optionally be substituted with a lower alkyl or a lower alkanoyl radical; R.sup.2 stands for hydrogen atom or hydroxyl group; R.sup.3 expresses hydrogen atom or formyl group; and means a double bond or a radical represented by ), and salts thereof.

Abstract: Imidazolyl phenoxy derivatives are provided as well as pharmaceutical compositions containing such derivatives. The compositions useful for lowering lipid activity in a subject and accordingly useful for reducing cholesterol and triglycerides.

Abstract: Pharmaceutical compositions for intranasal administration comprising (a) calcitonin and (b) at least one absorption enhancer selected from the group consisting of benzyl alcohol, ethanol, thiamine or a salt thereof, salicylic acid or a salt thereof, capric acid or a salt thereof, Macrogol 400, pyridoxal or a salt thereof, malic acid or a salt thereof and pyrophosphoric acid or a salt thereof, in (c) a liquid diluent or carrier, suitable for application to the nasal mucosa.

Abstract: Substantially pure neocarzinostatin anticancer agents have the formula (A):(SMA)--(NCS)--(SMA) (A)wherein (NCS) is a divalent neocarzinostatin residue and (SMA) comprises the monovalent residue of a partially half-esterified styrene-maleic acid copolymer having a weight-average molecular weight of from 800 to 2,500, said (NCS) residue being bonded to said (SMA) residues via amide linkages formed between primary amino groups of the neocarzinostatin molecule and carbonyl groups of the partially half-esterified styrene-maleic acid copolymer.

Abstract: A 1,4-dihydropyridine derivative represented by general formula (I): ##STR1## wherein: R.sup.1 and R.sup.2 : which may be the same or different, each represents an alkyl group which may be intervened by an oxygen atom, a cycloalkyl-substituted lower alkyl group or a halogen-substituted lower alkyl group;R.sup.3 and R.sup.4 : which may be the same or different, each represents a lower alkyl group;R.sup.5 and R.sup.6 : which may be the same or different, each represents a hydrogen atom, a nitro group, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfonyl group or a lower alkylsulfinyl group;R.sup.7 : hydrogen atom or a lower alkyl group;R.sup.8 : a lower alkyl group; a hydroxy-lower alkyl group, an aralkyl group, an aryl group, a lower acyl group, a lower alkylsulfonyl group or an aryloxy-lower alkyl group, an aryloxy-lower alkoxy group, provided that R.sup.7 and R.sup.

Abstract: A pharmaceutical controlled-release individual unit or multiple units formulation in which the individual unit comprises a granulation product obtained by adding a release controlling agent to a mixture of a physiologically active substance and units-forming substance(s) and granulating and resultant mixture, said granulation product (granules) being substantially not disintegrated but gradually releasing the physiologically active substance in the gastrointestinal tract.

Abstract: An oily composition of aclarubicin or aclarubicin hydrochloride comprising aclarubicin or aclarubicin hydrochloride; at least one fatty acid selected from saturated medium chain fatty acids, unsaturated medium chain fatty acids and unsaturated long chain fatty acids; and at least one fats and oils selected from iodized oils and vegetable oils.

Abstract: Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.

Abstract: Adhesive medical tapes for oral mucosa comprising a support layer composed of an intestine-soluble polymer and a medicament-containing layer composed of a water-soluble polymer containing at least one kind of a steroid or non-steroid antiphlogistic and analgesic medicament.

Abstract: A 7-formylaminocephalosporin compound represented by general formula (I): ##STR1## wherein R.sup.1 represents a carboxy group or an aminocarboxymethyl group ##STR2## R.sup.2 represents a hydrogen atom or a protective group for a carboxy group, andR.sup.3 represents a 5- or 6-membered heterocyclic group which may be substituted;or a salt thereof, and a process for producing the compound; The compounds are useful intermediates for other cephalosporin compounds having antibacterial activity, and themselves show antibacterial activity, as well.